CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2017--
Seres Therapeutics Inc. (NASDAQ:MCRB) today announced that management
will participate in two upcoming investor conferences:
Bank of America Merrill Lynch Healthcare Conference on Tuesday, May
16, 2017 in Las Vegas, NV; presentation at 3 p.m. PDT.
UBS Global Healthcare Conference on Monday, May 22, 2017 in New York,
NY; presentation at 1:30 p.m. EDT.
Live audio webcast of the presentations will be available under the
“Investors and Media” section of Seres’ website. A replay of the
presentations will become available after the event and will be archived
for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. A Phase 2 study
of Seres’ program SER-109 has been completed in multiply recurrent Clostridium difficile infection.
Seres’ clinical candidate, SER-287, is being evaluated in a Phase 1b
study in patients with mild-to-moderate ulcerative colitis (UC). Seres
is also developing SER-262, the first ever synthetic microbiome
therapeutic candidate, in a Phase 1b study in patients with primary CDI.
For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170501005134/en/
Source: Seres Therapeutics Inc.
Carlo Tanzi, Ph.D., 617-203-3467
Investor Relations and Corporate Communications